Patents by Inventor Richard D. Caldwell

Richard D. Caldwell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ABLATION PROBE AND LUMEN FOR IMPROVED ACCESS AND FLOW
    Publication number: 20240065751
    Abstract: An apparatus and method provide for the delivery of an ablation treatment by supplying a control signal to supply electrode of an ablation device disposed at the distal end portion of an elongated shaft. A lumen extends along a longitudinal axis of the shaft. The supply electrode forms an electrode face laterally directed from the longitudinal axis and through which an aperture extends in connection with the lumen. The electrode face forms an ovular shape having a first major axis that extends parallel to the longitudinal axis. An insulator separates the supply electrode from a return electrode, and a transition passage of the lumen extends though the insulator along an arc-shaped path.
    Type: Application
    Filed: August 10, 2023
    Publication date: February 29, 2024
    Applicant: Arthrex, Inc
    Inventors: Jeffrey Haczynski, Richard J. Taft, Stephen Donnigan, Jeremiah D. Caldwell
  • FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)
    Publication number: 20220389004
    Abstract: The present invention relates to fused imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Application
    Filed: August 26, 2019
    Publication date: December 8, 2022
    Inventors: Richard D. CALDWELL, Lesley LIU-BUJALSKI, Justin POTNICK, Constantin NEAGU, Shashank KULKARNI, Reinaldo JONES, Hui QIU
  • Heteroaryl compounds as BTK inhibitors and uses thereof
    Patent number: 11098041
    Abstract: Imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof are useful as BTK inhibitors.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: August 24, 2021
    Assignee: Merck Patent GmbH
    Inventors: Pascale Gaillard, Jeyaprakashnarayanan Seenisamy, Lesley Liu-Bujalski, Richard D. Caldwell, Justin Potnick, Hui Qiu, Constantin Neagu, Reinaldo Jones, Annie Cho Won, Andreas Goutopoulos, Brian A. Sherer, Theresa L. Johnson, Anna Gardberg
  • S1P modulating agents
    Patent number: 10894040
    Abstract: The present invention provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and their use in modulating the activity of S1P) receptors. Also provided is a pharmaceutical composition comprising the compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: January 19, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Jermaine Thomas, Sha Mi, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin Guckian, Gnanasambandam Kumaravel
  • S1P MODULATING AGENTS
    Publication number: 20200038385
    Abstract: Compounds of formula (I) or (II) can modulate the activity of S1P receptors.
    Type: Application
    Filed: August 16, 2019
    Publication date: February 6, 2020
    Inventors: Jermaine Thomas, Sha Mi, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin Guckian, Gnanasambandam Kumaravel
  • Heteroaryl compounds as BTK inhibitors and uses thereof
    Patent number: 10493073
    Abstract: The present invention relates to pyrimidine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: December 3, 2019
    Assignee: Merck Patent GmbH
    Inventors: Hui Qiu, Richard D. Caldwell, Lesley Liu-Bujalski
  • SIP modulating agents
    Patent number: 10406144
    Abstract: Compounds of formula (I) or (II) can modulate the activity of S1P receptors.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: September 10, 2019
    Assignee: BIOGEN MA INC.
    Inventors: Jermaine Thomas, Sha Mi, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel
  • HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF
    Publication number: 20190233417
    Abstract: Imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof are useful as BTK inhibitors.
    Type: Application
    Filed: April 8, 2019
    Publication date: August 1, 2019
    Inventors: Pascale Gaillard, Jeyaprakashnarayanan Seenisamy, Lesley Liu-Bujalski, Richard D. Caldwell, Justin Potnick, Hui Qiu, Constantin Neagu, Reinaldo Jones, Annie Cho Won, Andreas Goutopoulos, Brian A. Sherer, Theresa L. Johnson, Anna Gardberg
  • BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS
    Publication number: 20190209592
    Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
    Type: Application
    Filed: November 7, 2018
    Publication date: July 11, 2019
    Inventors: Jermaine Thomas, Xiaogao Liu, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Arthur G. Taveras
  • Heteroaryl compounds as BTK inhibitors and uses thereof
    Patent number: 10329270
    Abstract: The present invention relates to pyridine, pyrimidine, pyrazine, and pyridazine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: June 25, 2019
    Assignee: Merck Patent GmbH
    Inventors: Hui Qiu, Richard D. Caldwell, Constantin Neagu, Igor Mochalkin, Lesley Liu-Bujalski, Reinaldo Jones, Devon Tate, Theresa L. Johnson, Anna Gardberg
  • 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof
    Patent number: 10266528
    Abstract: The present invention relates to imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: April 23, 2019
    Assignee: Merck Patent GmbH
    Inventor: Richard D. Caldwell
  • Heteroaryl compounds as BTK inhibitors and uses thereof
    Patent number: 10253023
    Abstract: The present invention relates to imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: April 9, 2019
    Assignee: Merck Patent GmbH
    Inventors: Pascale Gaillard, Jeyaprakashnarayanan Seenisamy, Lesley Liu-Bujalski, Richard D. Caldwell, Justin Potnick, Hui Qiu, Constantin Neagu, Reinaldo Jones, Annie Cho Won, Andreas Goutopoulos, Brian A. Sherer, Theresa L. Johnson, Anna Gardberg
  • Bicyclic aryl sphingosine 1-phosphate analogs
    Patent number: 10166250
    Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: January 1, 2019
    Assignee: BIOGEN MA INC.
    Inventors: Jermaine Thomas, Xiaogao Liu, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Arthur G. Taveras
  • S1P MODULATING AGENTS
    Publication number: 20180369215
    Abstract: Compounds of formula (I) or (II) can modulate the activity of S1P receptors.
    Type: Application
    Filed: June 27, 2018
    Publication date: December 27, 2018
    Inventors: Jermaine Thomas, Sha Mi, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel
  • HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF
    Publication number: 20180318299
    Abstract: The present invention relates to pyrimidine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Application
    Filed: July 10, 2018
    Publication date: November 8, 2018
    Inventors: Hui QIU, Richard D. CALDWELL, Lesley LIU-BUJALSKI
  • Heterobicyclic sphingosine 1-phosphate analogs
    Patent number: 10081646
    Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: September 25, 2018
    Assignee: BIOGEN MA INC.
    Inventors: Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Wen-Cherng Lee, Edward Yin-Shiang Lin, Xiaogao Liu, Bin Ma, Daniel M. Scott, Zhan Shi, Jermaine Thomas, Arthur G. Taveras, Guo Zhu Zheng
  • Heteroaryl compounds as BTK inhibitors and uses thereof
    Patent number: 10045985
    Abstract: The present invention relates to pyrimidine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: August 14, 2018
    Assignee: Merck Patent GmbH
    Inventors: Hui Qiu, Richard D. Caldwell, Lesley Liu-Bujalski
  • S1P modulating agents
    Patent number: 10034869
    Abstract: The present invention provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and their use in modulating the activity of S1P receptors. Also provided is a pharmaceutical composition comprising the compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: July 31, 2018
    Assignee: BIOGEN MA INC.
    Inventors: Jermaine Thomas, Sha Mi, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel
  • Assays for BTK inhibitors
    Patent number: 10012650
    Abstract: The present invention relates to BTK occupancy assays.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: July 3, 2018
    Assignee: Merck Patent GmbH
    Inventors: Andrew Bender, Lesley Liu-Bujalski, Albertina Pereira, Richard D. Caldwell, Roland Grenningloh, Daigen Xu
  • Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof
    Patent number: 10005784
    Abstract: The present invention relates to pyridine, pyrimidine, and pyrazine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: June 26, 2018
    Assignee: Merck Patent GmbH
    Inventors: Lesley Liu-Bujalski, Ngan Nguyen, Hui Qiu, Reinaldo Jones, Igor Mochalkin, Richard D. Caldwell